Grace Therapeutics, Inc.

Grace Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing proprietary drug delivery formulations for rare and orphan diseases. The company is advancing a small pipeline of drug candidates, with GTx-104 as its lead program, and has not yet generated product revenue.

8.10

— Grace Therapeutics, Inc.
%
Lead drug candidate programs0% Clinical-stage product candidates being developed for rare and orphan disease indications.
Drug delivery technology platform0% Proprietary formulations designed to improve efficacy, onset, tolerability, and compliance of existing compounds.
Regulatory and development services0% Internal R&D, clinical development, and FDA submission work supporting pipeline advancement.
Future commercialization0% Potential post-approval sales, marketing, and distribution of approved drug products.

The company does not yet sell commercial products, so its near-term 'customers' are primarily regulators, clinical...

  • Regulators and clinical development partnersprimary

    FDA, CROs, and CMOs that support clinical testing, manufacturing, and approval pathways for the pipeline.

  • Future prescribing physicians and hospitalsprimary

    Specialists and care settings that would use approved products for rare and orphan disease treatment.

  • Payers and government reimbursement programssecondary

    Medicaid, Medicare Part B, 340B entities, and other payors that affect pricing and access after approval.

  • Strategic partners and licensorssecondary

    Potential commercialization partners for larger-market products such as GTx-101.

Grace Therapeutics is headquartered and operationally concentrated in the United States, where all six full-time...

  • •All full-time employees are located in the United States
  • •Clinical and regulatory work is centered on the U.S. market
  • •Potential commercialization is expected to start in the United States
  • •IP portfolio covers multiple jurisdictions worldwide
  • •No country revenue disclosure is available because there is no product sales base

The company’s strategy is to advance its rare-disease pipeline, complete development for GTx-104, and pursue FDA...

01
Advance GTx-104 to regulatory approvalshort-term

This is the lead asset and the most direct path to first commercial revenue.

02
Secure additional financingshort-term

The company expects continued operating losses and needs capital before cash runs out.

03
Build commercialization readinessmedium-term

Approval alone is not enough; the company needs sales, marketing, and distribution capability.

Grace Therapeutics is exposed to classic clinical-stage biotech risks: trial failure, regulatory delay, financing risk,...

critical

Clinical development failure or delay

The company depends on successful trials and FDA approval to create any product revenue.

Scope
GTx-104, GTx-102, GTx-101
Materiality
high
critical

Financing and liquidity shortfall

Management expects to need additional capital before current resources are exhausted.

Scope
Operating runway into third calendar quarter of 2026
Materiality
high
high

Manufacturing and supply chain disruption

Clinical and future commercial supply depend on third-party CMOs meeting cGMP and quality requirements.

Scope
Clinical materials and scale-up
Materiality
high
high

Intellectual property challenges

Third-party patent claims or weak protection could limit commercialization or increase costs.

Scope
Drug delivery technologies and pipeline candidates
Materiality
high
medium

Reimbursement and pricing pressure

Medicaid, Medicare Part B, and 340B rules can reduce realized pricing after approval.

Scope
U.S. commercial launch
Materiality
medium
Research and development accruals
Can shift quarterly R&D expense and liabilities
Derivative warrant liabilities
Can materially affect net income/loss
Intangible asset and goodwill impairment
Could cause large impairment charges
Stock-based compensation
Raises operating expenses and affects per-share results

GT Biopharma, Inc.

GTBP · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTAW · Pharmaceutical Preparations

Werewolf Therapeutics, Inc.

HOWL · Pharmaceutical Preparations

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

: 28/04/2026